Navigation Links
Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Date:1/10/2008

, it is estimated that approximately 40% of people aged 65 and above, or 16 million, have AAMI. It is characterized by gradual memory impairment (subjective memory decline and objective memory loss) with the absence of dementia. Individuals with AAMI have been shown to have a three-fold greater risk for development of dementia than individuals who do not meet AAMI criteria.

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms, a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.

Disclosure Notice

The information contained in this document is as of January 10, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
(Date:3/25/2015)... 25, 2015 An increase of awareness ... all forms of food nutrients, regulatory changes and concerns ... rise in demand for natural astaxanthin over the past ... ramp up their capacities to satisfy the rising demand. ... synthetic source astaxanthin (used in nutraceuticals, aqua feed, food ...
(Date:3/25/2015)... 2015 Data from Evidence of ... Action in Neuromuscular Diseases , South San ... (Nasdaq: CYTK) announced the publication of a manuscript ... tirasemtiv in the journal Neurotherapeutics. This publication ... Effect” or hypothesis-generating clinical trial which evaluated tirasemtiv ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. have ... enable broader and less invasive screening for cancer, ... breath screen. The Minnesota-based medical device maker will ... Administration (FDA) approval process and is targeting a ... Tagging device. , Ancon Medicals nanoparticle breakthrough comes ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... announced an agreement Thursday with Capital ... technology solutions and financial services, according to TeraMEDICA's ... agreement, Capital Data will bundle TeraMEDICA's TI2m archive ... solutions in a territory that includes Wisconsin, Minnesota, ...
... Bryan Bechtoldt, Lauri Meixelsperger and Charlie Eaton, and ... was recently named Worldwide Learning Solutions Partner ... Partner Conference 2004 . Inacom received this award ... to deliver solutions that exceeded its customers' expectations. ...
... Dale Jenssen, one of about 10,000 works available through ... a dot-com. The art-dealer network Guild began in 1985 ... professionals. The idea was to enable artists to market ... , ,Founder and CEO Toni Sikes expanded her distribution ...
Cached Biology Technology:TeraMEDICA and Capital Data enter into diagnostic imaging agreement 2Inacom named Microsoft's favorite learning solutions partner of the year 2Guild.com: The art of evolving online 2Guild.com: The art of evolving online 3Guild.com: The art of evolving online 4
(Date:3/17/2015)... SAN DIEGO , March 17, 2015 /PRNewswire/ ... and emotion analytics software, today announced general availability ... on-demand web service for the analysis of facial ... they experience advertising, media content, products and services. ... customer attention, engagement and sentiment - as derived ...
(Date:3/16/2015)... Germany , March 16, 2015 ... Identification Systems GmbH will present groundbreaking innovations in ... Hanover, Germany .      ... DERMALOG,s latest biometric innovation is well at the ... next generation e-gate made in Germany ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... the biology textbooks back to the printer. In a new ... geochemist with the Woods Hole Oceanographic Institution (WHOI) and his ... have come up with a completely unexpected way of building ... cells are surrounded by membranes containing molecules called phospholipids ...
... fungus foils dangerous grapefruit-drug interactions, Journal of Agricultural ... that adding an edible mushroom-like fungus to grapefruit juice ... can occur when people taking certain prescription drugs drink ... edition of the ACS, bi-weekly Journal of Agricultural ...
... WI, February 2, 2009 -- Over the past decade, ... soybean crop earlier because they believe that earlier planting ... most important yet least expensive management decisions that significantly ... effect of early-planting dates on soybean yield components and ...
Cached Biology News:Phytoplankton cell membranes challenge fundamentals of biochemistry 2American Chemical Society's Weekly PressPac -- Jan. 28, 2009 2American Chemical Society's Weekly PressPac -- Jan. 28, 2009 3American Chemical Society's Weekly PressPac -- Jan. 28, 2009 4American Chemical Society's Weekly PressPac -- Jan. 28, 2009 5American Chemical Society's Weekly PressPac -- Jan. 28, 2009 6Plant soybean early to increase yield 2
...
... The new IKATUBE ULTRA TURRAX Tube Disperser ... closed homogenizing system. It offers a cleaner, safer, ... IKATUBE system processes sample volumes from 2 to ... sample type, researchers can choose one of 4 ...
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
Biology Products: